ReviewNutrients2025
Obesity and Diabetes in Mexico: An Approach to the Intestinal Microbiota.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and diabetes have reached alarming prevalence rates globally, with Mexico being one of the most affected countries. This review explores the epidemiology of these metabolic disorders and analyzes their prevalence and risk factors, as well as the crucial role of the intestinal microbiota in their development. Obesity and diabetes in Mexico have been linked to lifestyle factors, genetic predispositions, and alterations in the gut microbial composition. The intestinal microbiota plays a significant role in metabolic regulation, and its dysbiosis has been associated with insulin resistance, chronic inflammation, and increased fat accumulation. Studies in Mexico have highlighted specific microbial patterns in individuals with obesity and diabetes, suggesting a unique interplay between diet, microbiota composition, and metabolic health. Strategies to restore microbial balance, such as dietary modifications and probiotic interventions, have shown promising results in improving metabolic parameters and reducing disease progression. However, challenges remain in understanding the long-term effects of microbiota-targeted therapies and their individual variability. This review underscores the need for further research to develop personalized interventions aimed at modulating the gut microbiota for obesity and diabetes management. Future directions should focus on integrative approaches combining nutrition, prebiotics, and microbiome-based therapeutics to combat the increasing burden of metabolic diseases in Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.